APA (7th ed.) Citation

SJ, Z., DH, W., YW, L., L, H., X, X., M, M., . . . Y, M. (2017). A novel selective VPAC2 agonist peptide-conjugated chitosan modified selenium nanoparticles with enhanced anti-type 2 diabetes synergy effects. Dove Medical Press.

Chicago Style (17th ed.) Citation

SJ, Zhao, Wang DH, Li YW, Han L, Xiao X, Ma M, Wan DC, Hong A, and Ma Y. A Novel Selective VPAC2 Agonist Peptide-conjugated Chitosan Modified Selenium Nanoparticles with Enhanced Anti-type 2 Diabetes Synergy Effects. Dove Medical Press, 2017.

MLA (8th ed.) Citation

SJ, Zhao, et al. A Novel Selective VPAC2 Agonist Peptide-conjugated Chitosan Modified Selenium Nanoparticles with Enhanced Anti-type 2 Diabetes Synergy Effects. Dove Medical Press, 2017.